Viral concentrations are frequently determined using the plaque assay, which is 64 based on the principle that each plaque represents one infectious unit (1). Many 65 mammalian viruses have high particle to plaque-forming unit (PFU) ratios due to various 66 factors such as assembly defects, mutations, and inefficient steps during the viral 67 replication cycle (2) (3) (4) . For most mammalian viruses, the number of plaques is directly 68
proportional to the concentration of virus. This indicates that one infectious particle 69
gives rise to one plaque, providing a "one hit" model for plaque formation. However, 70 certain viruses of plants and fungi have a "two hit" model, whereby two particles 71 containing different genome segments are required to co-infect the same cell to 72 facilitate productive infection and plaque formation (5, 6) . Recently, Ladner et al. 73 reported that a mammalian virus has a "three hit" model (7) . This virus is composed of 74 five genome segments, each packaged in five separate viral particles; however, a 75 minimum of three segments were required to facilitate productive infection. While 76 previous work indicates that, for most mammalian viruses, plaque number appears to 77 correlate linearly with the dilution of virus plated, it is possible that some plaques may 78 be the products of co-infection. 79 Several mechanisms could facilitate co-infection of viruses. Previous reports 80 demonstrated that cells may be infected by more than one virus at a higher frequency 81 than predicted by Poisson distribution (8) (9) (10) (11) (12) . For example, poliovirus can be packaged 82 in phosphatidylserine vesicles, which promotes co-infection of neighboring cells (8) . 83
Multiple coxsackievirus B3 and hepatitis A virions can also be packaged in vesicle-like 84 structures (13, 14) . Vesicular stomatitis virus was found to form plaques containing two 85 different viral genomes, indicating that co-infection occurred (9). Additionally, many 86 different viruses aggregate in solution and could induce co-infection (15) (16) (17) (18) . Viral 87 stocks of vaccinia virus, influenza virus, adenovirus, herpes virus, and echovirus 88 contained virion aggregates that were resistant to antibody-mediated neutralization 89 and/or radiation (18, 19) . Poliovirus and reovirus particles can aggregate in sewage, 90 which may contribute to initial infection of the host and it is possible that virion 91 aggregates exist in vivo (20, 21) . 92
RNA viruses undergo error-prone replication due to lack of proofreading activity 93 of their RNA-dependent RNA polymerase (RdRp). For poliovirus, the mutation 94 frequency is ~10 -4 per nucleotide per replication cycle (22) . Mutations can be beneficial 95 to viruses in some circumstances, for example by conferring resistance to neutralizing 96 antibodies. However, most mutations are deleterious and reduce viral fitness (23). Much 97 has been learned about RNA virus mutation-associated fitness effects from viral 98 populations harboring increased or decreased mutation frequencies. Crotty et al. 99 demonstrated that the nucleoside analog ribavirin (RBV) is an RNA virus mutagen. RBV 100 is incorporated into nascent RNA by the viral RdRp, which increases transition 101 mutations and can cause "error catastrophe" (24). Conversely, poliovirus passaged in 102 the presence of RBV acquired a single point mutation in the RdRp, G64S, which 103 increased fidelity of viral RNA synthesis and reduced the error frequency of the viral 104 population (25, 26) . Importantly, G64S poliovirus had reduced viral fitness during 105 infection of mice, indicating that viral population diversity is necessary for virulence 106 (27, 28) . 107
RNA viruses may overcome mutation-induced fitness costs by several genetic 108 mechanisms (23). First, deleterious mutations may revert via error prone RNA 109 synthesis. Second, genetic recombination can generate progeny genomes lacking 110 deleterious mutations. Recombination can occur when two viruses co-infect the same 111 cell and exchange genetic information, likely through a copy-choice mechanism (29). 112
Recombination of genomes has been observed in poliovirus and other enteroviruses 113
(30-36). Furthermore, defective RNA genomes are capable of undergoing 114 recombination in vivo, thus restoring their fitness (36). Third, fitness may be restored by 115 complementation, whereby viruses with distinct genetic defects complement one 116 another. Complementation has been observed within brain tissues of poliovirus-infected 117 mice (28). Fourth, reassortment can occur when two distinct segmented viruses co-118 infect the same cell and generate progeny with genome segments from both viruses. 119
Unlike reversion, fitness restoration by recombination, complementation, and 120 reassortment generally requires synchronous co-infection of a cell with more than one 121 virus. Overall, these genetic processes can alter viral diversity and increase fitness. 122
In this work, we examined whether viral plaques are derived from a single 123 founder and whether viruses with increased genome damage may be more reliant on 124 co-infection for plaque formation. Through the use of a genetic assay with ten distinct 125 polioviruses and a phenotypic assay with two distinct polioviruses, we have shown that 126 multiple parental viruses can be found within a single plaque, which we refer to as a 127 chimeric plaque. We determined that 5-7% of plaques were derived from two or more 128 viruses. To assess factors contributing to co-infection, we used dynamic light scattering 129
and electron microscopy to demonstrate that viral stocks contain both single particles 130 and aggregates, suggesting that infection with virion aggregates is likely responsible for 131 chimeric plaque formation. Indeed, inducing virion aggregation via exposure to low pH 132 increased co-infection frequency in a separate flow cytometry-based assay. We 133 examined whether there were situations where co-infection frequencies varied and 134 whether co-infection may assist plaque formation. Using high fidelity G64S polioviruses 135 that harbor fewer mutations than wild-type (WT) and RBV-mutagenized polioviruses that 136 harbor more mutations than WT, we found that co-infection frequency correlated with 137 mutation load. In fact, 17% of plaques from mutagenized virus infections were the 138 product of co-infection. This work indicates more than one virus can contribute to plaque 139 formation and that co-infection may assist plaque formation in situations where the 140 amount of genome damage is high. 141
142

RESULTS 143
A small percentage of plaques are derived from more than one parental virus. To 144 determine whether plaques are the product of more than one founding virus, distinct 145 parental viruses that can be discriminated by genotype or phenotype are required. We 146 began by using ten genetically distinct polioviruses that each contain unique silent point 147 mutations and are discriminated by hybridization of RT-PCR products with specific 148 probes. We previously demonstrated that these ten marked viruses are equally fit (37-149 39). We mixed equal amounts of the ten viruses and infected HeLa cells at an extremely 150 low MOI such that ~2-20 plaques would be generated on each plate of 10 6 cells ( Fig.  151 1A). Plaques were picked, viruses were amplified for a single cycle in HeLa cells, and 152 the presence of each virus was determined by probe-specific hybridization of RT-PCR 153 products (37-39). Plaques were scored as having a single parent virus (e.g. Plaque 1) 154 or more than one parent virus (e.g. Plaque 2) ( Fig. 1B) . We examined whether each of 155 the ten viruses were equally represented in plaques since skewed ratios of the input 156 viruses could impact the observed frequency of co-infection. The distribution of viruses 157 present within all plaques tested was reasonably even, with each of the ten viruses 158 nearly equally represented ( Fig. 1C ). Of 123 total plaques analyzed, 6 had more than 159 one founding parental viruses and 117 had a single virus (Table 1) . Therefore, 4.9% of 160 plaques were derived from more than one parental virus. 161
It was possible that overlapping plaques with single parental viruses were picked 162 and incorrectly scored as chimeric. If so, the frequency of chimeric plaques should be 163 higher on plates with more plaques present. To rule out the possibility that picking dual-164 parent plaques was enriched in situations where a higher number of plaques were 165 present on the plate, we compared the number of plaques on plates from single and 166 dual parent plaques ( Fig. 1D ). We found that dual parent plaques were not more 167 prevalent on plates with higher plaque numbers, indicating that cross-contamination of 168 plaque viruses was unlikely. 169
Since the ten virus genotypic assay to measure co-infection is relatively labor 170 intensive, we sought to simplify the screening process by using a previously 171 characterized poliovirus mutant that can be discriminated from WT by a phenotypic 172 assay (29) ( Fig. 2A ). 3NC-202gua R poliovirus has mutations that confer resistance to 173 guanidine hydrochloride and temperature sensitivity (called Drug R /Temp S hereafter). 174
Guanidine is used as a protein denaturant but can also specifically inhibit poliovirus 175 RNA synthesis (40). Conversely, WT poliovirus is guanidine sensitive and temperature 176 resistant (called Drug S /Temp R hereafter). We mixed equal amounts of Drug R /Temp S and 177 Drug S /Temp R polioviruses and infected HeLa cells at an extremely low MOI such that 178 ~2-20 plaques would be generated on each plate of 10 6 cells. Infections were incubated 179 in permissive conditions for both parental viruses (33°C without drug). Plaques were 180 picked and analyzed by their growth phenotypes to determine whether one or both 181 parental viruses were present. Plaque formation at 33°C in the presence of drug 182 indicated the presence of the Drug R /Temp S parent. Plaque formation at 39°C indicated 183 the presence of the Drug S /Temp R parent. Plaque formation in both conditions indicated 184 presence of both parental viruses (Fig. 2C ). The distribution of viruses present within 185 plaques was reasonably even, with 44.2% and 55.8% of Drug S /Temp R and 186
Drug R /Temp S parental viruses, respectively (Fig. 2C ). In this assay, we found that 10 187 out of 138 (7.3%) plaques had more than one parental virus present (Table 1) . 188
Therefore, both the genotypic and phenotypic assays indicate that ~5-7% of plaques 189 that arise following infection of HeLa cells contain more than one distinct parental virus. 190
191
Poliovirus stocks contain viral aggregates. To examine whether co-infection of 192 poliovirus may be due to viral aggregation, we examined representative viral stocks 193 using visual and biophysical assays. We first examined viruses using electron 194 microscopy and observed single viral particles as well as aggregated viral particles (Fig. 195 3A), in agreement with previous studies (15-17). To quantify poliovirus aggregation, we 196 used dynamic light scattering, which measures the size of particles in solution. Using 197 this assay, we observed that our viral stock contained both single particles (15 nm 198 radius) and aggregates ranging from 2-10 particles (Fig. 3B ). Overall, these results 199
indicate that viral stocks contain aggregates and we speculated that virion aggregation 200 facilitates co-infection of viruses. 201 202 Inducing aggregation increases co-infection frequency. To test the hypothesis that 203 virion aggregation facilitates co-infection, we examined co-infection frequency for virions 204 exposed to conditions that induce aggregation using a minimally labor-intensive flow 205 cytometry-based assay. Polioviruses expressing either GFP or DsRed (41) were mixed 206 and incubated for 4 h in PBS (control) or in glycine-HCL buffer, pH 3, which induces 207 aggregation of poliovirus (15-17) ( Fig. 4A ). Viruses were then used to infect HeLa cells 208
at an MOI of 0.01, such that ~99% of cells remain uninfected. Sixteen hours post-209 infection, cells were subjected to flow cytometry to quantify the percentage of 210 uninfected, singly infected (red or green), or co-infected cells (red and green, dual 211 positive). To ensure that the low pH treatment induced virion aggregation, we measured 212 particle size using dynamic light scattering. Indeed, viruses exposed to low pH had 213 increased radii compared with viruses exposed to PBS, confirming that low pH induced 214 virion aggregation (Fig. 4B ). Based upon an MOI of 0.01, approximately 1% of cells 215 infected with PBS-treated viruses were infected with a single virus ( Fig. 4C ). However, 216 0.83% of cells infected with low pH-treated viruses were infected with a single virus, 217
suggesting that virion aggregation slightly reduced the total number of infectious units. A 218 small percentage, 0.0048%, of cells infected with PBS-treated viruses were co-infected 219 with both DsRed-and GFP-expressing viruses (Fig. 4D ), which is close to the predicted 220 number of co-infected cells based on Poisson distribution (0.005%). Interestingly, co-221 infection was increased 2.6-fold in low pH-treated viruses, suggesting that aggregation 222 enhances co-infection. Furthermore, these data indicate that co-infection can occur 223 during infections performed in liquid culture. 224 225 Co-infection frequency correlates with mutation frequency. We hypothesized that 226 co-infection would rescue plaque formation for heavily mutagenized viruses due to 227 processes such as complementation and recombination. Conversely, we hypothesized 228 that viruses with fewer mutations would be less reliant on co-infection for plaque 229 formation. To test this, we compared chimeric plaque frequencies of virus stocks with 230 low, intermediate, or high mutation frequencies (Fig. 5) which confers higher fidelity. G64S-RdRp viruses and WT-RdRp viruses were equally fit 235 in cell culture and grew to similar titers, but G64S-RdRp viruses had 4.5-fold fewer 236 mutations than WT-RdRp viruses, in agreement with previous studies (Table 2) (25, 26) . 237
To test viruses with high error frequencies, we used Drug S /Temp R and Drug R /Temp S 238 viruses passaged in the presence of RBV. For each virus, we infected HeLa cells in the 239 presence of 800 μM RBV for a single cycle of replication, harvested progeny viruses 240 and repeated this cycle 4-5 times to generate mutagenized viral populations. In 241 agreement with previous studies, these mutagenized viruses had reduced fitness, with 242 8.3-fold lower titers and 21-fold more mutations than viruses passaged in the absence 243 of RBV (Table 2 )(24). To confirm that mutagenized viral genomes had reduced specific 244 infectivity compared with non-mutagenized WT-RdRp or G64S-RdRp viral genomes, 245 viral RNA was extracted from 1 x 10 6 PFU and quantified by qRT-PCR. Indeed, RBV-246 mutagenized viruses required 2.5-fold or 3.4-fold more RNA to form the same number 247 of plaques as WT-RdRP or G64S-RdRp viruses, respectively (Table 2) . Therefore, 248 these mutagenized viruses formed fewer plaques than non-mutagenized viruses due to 249 reduced specific infectivity of their RNA genomes ( (G64S-RdRp) or low fidelity (WT-RdRp + RBV)] and determined the co-infection 252 frequency using the phenotypic assay (Fig. 2, Fig. 5A ). We observed that the co-253 infection frequency with G64S-RdRp viruses was decreased (3.2%) in comparison to 254 the WT-RdRp viruses (7.3%) ( Fig. 5B, Table 2 ). Additionally, viruses passaged in the 255 presence of RBV had the highest percentage (16.7%) of co-infection (Fig. 5B) . Overall, 256 these data show that co-infection frequency correlates with the error frequency of the 257 viral population, with increased co-infection among plaques generated by heavily 258 mutagenized viruses. 259
260
DISCUSSION 261
Co-infection of RNA viruses can promote genetic diversity and emergence of 262 novel viruses. We found that some plaques are the result of co-infection and contain 263 two or more parental viruses. Furthermore, we determined that co-infection frequency 264
correlates with the level of mutation-induced genome damage. Importantly, these 265 effects would have been masked had we not used genetically distinct viruses. 266
Our data show that 3-17% of plaques contain more than one founding virus. 267
These data fall out of line with the 'one hit' model for plaque formation whereby one 268 infectious particle gives rise to one plaque (Fig. 6 , calculation depicted by dotted black 269 line). Certain viruses of plant and fungi have a two hit model, whereby two particles 270 containing different genome segments are required to co-infect the same cell to 271 facilitate productive infection (Fig. 6 , calculated depicted by dotted red line) (5,6). We 272 used our observed percentages of chimeric plaques to calculate the theoretical 273 relationship between virus dilution and number of plaques. As shown in Figure 6 , these 274 lines all fall between the one hit and two hit model lines, although all are much closer to 275 the one hit model line. Nonetheless, even this relatively low level of co-infection confers 276 a slight "bend" to the one-hit model line, particularly for RBV-mutagenized viruses. 277
These results indicate that the relationship between viral dilution plated and number of 278 plaques is not linear, particularly for mutagenized viruses. Furthermore, even at 279 extremely low MOIs, cells may be infected with more than one virus at a higher 280 frequency than predicted by Poisson distribution. 281
Although the data presented here indicate that 3-17% of plaques arose from co-282 infection of two different parental viruses, the actual frequency is likely higher because 283 only one-third of possible co-infection events are observable in our phenotypic assay. 284
For example, co-infection with the same parental virus (e.g., Drug S /Temp R + 285 Drug S /Temp R or Drug R /Temp S + Drug R /Temp S ) is scored as single parent plaques in the 286 phenotypic assay. Additionally, the presence of three or more parental viruses cannot 287 be scored by the phenotypic assay. Indeed, using our genotypic assay, one plaque 288 contained three of the ten parental viruses (data not shown). Furthermore, pre-289 aggregated viruses within parental virus stocks may limit even "mixing" and re-290 aggregation with viruses from other parental virus stocks, which could limit observable 291 co-infection in our system. Therefore, our observed chimeric plaque frequencies (3-292 17%) are likely underestimates and the actual frequency of plaques containing more 293 than one parental virus could be up to three times higher. For non-mutagenized viral 294 populations, these frequencies of chimeric plaques would still fall relatively close to the 295 linear one-hit model line (e.g., the green line in Fig. 6 ), making standard plaque assay 296 dilution series appear nearly linear and/or within standard deviation of the assay. 297
However, for mutagenized viral populations, the relationship between dilution plated and 298 plaque number could become non-linear enough to affect quantification of virus 299 concentration. If our observed chimeric plaque frequency is underestimated by three-300 fold for mutagenized viruses, 50% of plaques would be the product of co-infection and 301 the relationship between dilution plated and plaque number becomes obviously non-302 linear (see orange line in Fig. 6 ). Although our observed co-infection frequencies may 303 be underestimates, several factors may limit productive co-infection. For example, some 304 virions in a population are non-viable because they lack a genome and therefore cannot 305 productively infect or co-infect a cell. Additionally, virion aggregates in our stocks were 306 generally composed of a small number of virions. These types of factors pose an upper 307 limit on co-infection frequency and chimeric plaque formation. 308
Our work demonstrates that plaque formation correlates with the amount of 309 genome damage present within the viral genome, perhaps due to restoration of fitness 310 via recombination or complementation. Given that RNA viruses have high particle to 311 PFU ratios, partly because of mutations, it is possible that co-infection-mediated fitness 312 restoration could promote 'viral resurrection' of defective genomes. Overall, our findings 313 indicate that multiple virions can contribute to plaque formation. 314
315
MATERIALS AND METHODS 316
Cells and viruses. HeLa cells were propagated in Dulbecco's modified Eagle's medium 317 (DMEM) supplemented with 10% calf serum and 1% penicillin/streptomycin. All 318 infections were performed using viruses derived from Mahoney serotype 1 infectious 319 cDNA clone variants containing WT-RdRp, G64S-RdRp, with or without 3NC-202gua R 320 mutations (see Fig. 5A for schematic) (25,29) . The 3NC-202gua R virus contains two 321 mutations that confer guanidine resistance (2C-M187L and 2C-V250A) and an insertion 322 in the 3' non-coding region that confers temperature sensitivity (3-NC202) (29, 42) . To 323 generate highly-mutagenized poliovirus, 1 x 10 6 HeLa cells were pre-treated with 800 324 μM RBV (Sigma) for 1 h. Approximately 1 x 10 5 plaque-forming units (PFU) of virus was 325 used to infect the cells for 30 min at 37°C and 5% CO 2 . Unattached virus was washed 326 with PBS and media containing 800 μM RBV was added to the cells. Virus was 327 harvested at approximately 7 hours post infection (hpi) in 1 mL phosphate-buffered 328 saline supplemented with 100 μg/mL CaCl 2 and 100 μg/mL MgCl 2 (PBS+). Passage of 329 virus in the presence of RBV was repeated 4-5 times. For the genotypic assay, ten 330 polioviruses derived from Mahoney serotype 1, each containing unique silent point 331 mutations in the VP3-capsid coding region, were used as previously described (37). 332 333 Quantifying dual parent vs. single parent plaque viruses. The ten polioviruses 334 containing unique silent point mutations were mixed in equivalent amounts with PBS+ 335 and incubated at 37°C for 1 h. After incubation, the viral mixture was diluted to a 336 multiplicity of infection (MOI) of ~0.00001 and plated onto 10 cm plates seeded with 1 x 337 10 6 HeLa cells. After attachment, unbound virus was removed and an agar overlay was 338 added as previously described (25). Plates were incubated at 37°C and 5% CO 2 for 48 339 h, plaques were picked, and plaque agar plugs were placed into tubes containing 1 ml 340 PBS+. Plaque stocks were freeze-thawed three times to release virus and 200 μl of 341 these viruses were used to infect fresh HeLa cells to generate viral RNA for analysis of 342 parental viruses. At 6 hpi, total RNA was isolated using TRI-Reagent (Sigma-Aldrich) 343
according to the manufacturer's instructions. cDNA synthesis, PCR, blotting, and 344 hybridization using 32 P-labeled oligonucleotide probes specific for each of the ten viral 345 sequences was performed as previously described (37). 346
In the phenotypic assay, 1 x 10 5 PFU of Drug S /Temp R poliovirus and 347
Drug R /Temp S poliovirus were incubated in PBS+ for 1 h at 37°C. After incubation, the 348 viral mixture was diluted to a MOI of ~0.00001 and plated onto 10 cm plates seeded 349
with 1 x 10 6 HeLa cells. After attachment, unbound virus was removed and agar overlay 350 was added as previously described (25). Plates were incubated at 33°C and 5% CO 2 in 351 the absence of guanidine hydrochloride (Sigma) for 4-5 days. Plaques were picked and 352 placed into tubes containing 1 mL PBS+. To release virus, plaques stocks were freeze-353 thawed three times prior to screening. Plaque viruses were screened by performing 354 plaque assays under selective growth conditions (33°C with 1 mM guanidine or 39°C 355 without guanidine). To ensure that phenotypes could be discriminated accurately, trial 356 blinded experiments were performed and Drug S /Temp R vs. Drug R /Temp S viruses were 357 correctly scored. Of several hundred plaques that were picked during the course of this 358 study, 14 did not contain detectable virus and were not included in the analysis. It is 359 likely that these "plaques" were non-viral defects in the monolayer. Because no 360 detectable virus was present in these samples, it is unlikely that inefficient/abortive 361 infections that yield low-level virus are common in our system. 362 363 Analysis of poliovirus aggregation by electron microscopy. Poliovirus stocks were 364 purified by cesium chloride gradient centrifugation and were concentrated and desalted 365 using Amicon filters (Millipore) as previously described (43). Poliovirus samples 366 containing 9.3 x 10 6 PFU were inactivated by treating with 2.5% glutaraldehyde for 1 h 367 at room temperature. After inactivation, 2.5 µl of the inactivated virus was placed on 400 368 mesh carbon-coated copper grids that had been glow discharged for 30 s using PELCO 369
EasiGlow™ 91000. Grids were stained with 2% phosphotungstic acid and examined 370 using a TEI Technai G 2 Spirit Biotwin transmission electron microscope (FEI, Hillsboro, 371 OR) equipped with a Gatan ultrascan CCD camera, operated at an acceleration voltage 372 of 120 kV. Images were taken at a magnification of 13,000x and 30,000x. 373 374 Quantifying poliovirus aggregation using dynamic light scattering. Samples of 5 x 375 10 4 PFU gradient purified poliovirus (see electron microscopy methods above) were 376 prepared in a total volume of 20 µL and samples were centrifuged at 10,000 rpm for 10 377 min before data acquisition to remove dust or contaminants. Experiments were 378 37°C. The cells were washed with PBS and 2 mL of DMEM supplemented with 5% calf 394 serum and 1% penicillin/streptomycin was added to each well. After incubation for 16 h 395 at 37°C and 5% CO 2 , cells were harvested using 0.1% trypsin/0.05% EDTA solution, 396 washed and fixed with 2% paraformaldehyde fixation solution for 15 min at room 397 temperature and resuspended in 300 μL 2% fetal bovine serum/PBS. Expression of 398 GFP and DsRed was determined using a FACSCalibur cytometer equipped with 488-399 and 635-nm lasers. FACS data were analyzed using FlowJo software. Given the low 400 MOI, a relatively large number of cells (2 x 10 5 ) were counted for each experimental 401 condition. Experiments performed with a range of MOIs demonstrated that the 402 conditions used here were in the linear range and above the detection limit (data not 403 shown). Additionally, the observed co-infection frequency of 0.0048% is nearly identical 404 to the co-infection frequency predicted by Poisson's distribution (0.005%) (Fig. 4E) . 405
Gates were determined using uninfected cells or singly infected cells as indicated in the 406 legend for Figure 4 . 407 408 Quantifying mutation frequency of viruses. Error frequencies were determined by 409 acquisition of guanidine resistance, as previously described (25). Because the 410 Drug R /Temp S viruses are uninformative for this assay, we scored the frequency of 411 guanidine resistance in the Drug S /Temp R viruses (grown in parallel with the 412 Drug R /Temp S viruses) in the 1) WT-RdRp background, 2) G64S-RdRp background, or 413
3) WT-RdRp background mutagenized with RBV (see Fig. 4A for schematic). Viral 414 dilutions were plated on approximately 1 x 10 6 HeLa cells to determine viral titer by 415 plaque assay at 33°C and 39°C in the presence or absence of 1 mM guanidine 416 hydrochloride. The error frequencies were determined by dividing PFU/mL obtained in 417 the presence of drug by PFU/mL in the absence of drug. Note that the highest observed 418 error frequency (Drug R reversion frequency) was 1.6 x 10 -3 , meaning that 1 in every 625 419 viruses lost the guanidine resistance phenotype. Because the number of plaques 420 screened in the phenotypic assay is much lower than this reversion frequency, it is 421 unlikely that gain or loss of the Drug R marker impacted quantification of co-infection. To 422 quantify the relative specific infectivity for WT-RdRp, G64S-RdRp, and WT-RdRp + RBV 423 stocks, RNA was extracted from 1 x 10 6 PFU of each stock using TRI-Reagent (Sigma) 424 with carrier RNA from 10 6 HeLa cells, and quantification of poliovirus RNA was 425 performed using quantitative RT-PCR. Reverse transcription was performed with 426 Superscript II (Invitrogen) using an antisense primer 5′ TGTAACGCCTCCAAATTCCAC 427 3′ in the VP2-capsid coding region. To perform qPCR, 5 μL of the cDNA reaction was 428 mixed with SYBR green PCR master mix reagent (Applied Biosystems) and 10 μM of 429 each primer. The VP2 capsid region was amplified with the sense primer 5 ' 430 TGAGGGACATGGGACTCTTT 3' and the antisense primer above using an Applied 431
Biosystems 7500 system. Cycling conditions were: 1 cycle for 2 min at 50°C and 10 min 432 at 95°C, followed by 40 cycles of 15 sec at 95°C and 1 min at 60°C. The qPCR 433 reactions were performed in duplicate from two independent RNA preparations and 434 quantified using standard curve generated with poliovirus plasmid DNA samples. 435
Analysis of standard curve and data were determined as previously described (44, 45) . 436 Specific infectivity was determined by dividing 1 x 10 6 PFU by the relative RNA amounts 437 (Table 2) . 438 439
Relationship between virus dilution and plaque numbers at different co-infection 440
frequencies. To generate the graph shown in Figure 6 , we used the following formula 441 to calculate the predicted number of plaques generated by several dilutions of virus over 442 a range of co-infection frequencies: [(Dilution) 1 x Fraction with 1 Virus] + [(Dilution) 2 x 443
Fraction with 2 Viruses]= # Plaques. 444
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